This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

The Yale Experience

Irvin M. Modlin, MD, PhD; Christopher J. Gilligan, MPhil; Gary P. Lawton, MD; Laura H. Tang, MD, PhD; A. Brian West, MB, MRCPath; Umer Darr, MD

Arch Surg. 1995;130(3):250-256.

Abstract
Objectives
To document our experience with gastric carcinoids over the past decade and to identify lesion frequency and the existence of a relationship to low acid states.

Design
Retrospective case series.

Setting
Tertiary care referral center.

Patients
A consecutive sample of 16 patients with gastric carcinoids was evaluated over the last decade. Only two cases were recorded in the prior decade. Ages ranged from 30 to 93 years (mean, 65.9 years). There were eight men and eight women. Three patients were unavailable for follow-up.

Interventions
Therapy included total gastrectomy (n=4), subtotal gastrectomy (n=3), endoscopic polypectomy (n=3), and endoscopic surveillance (n=6).

Main Outcome Measures
Pathobiological tumor charcteristics and survival.

Results
All carcinoids were of gastric fundic origin. None of the patients exhibited the carcinoid syndrome. Chronic atrophic gastritis was the most frequently observed comorbid pathologic condition (63%). Half of the patients had multiple polypi. Mean follow-up was 4.7 years (n=13). There were 10 survivors. The only related death occurred in a patient with a solitary tumor.

Conclusions
Diagnosis of the complex and illdefined entity of gastric carcinoid is increasing. This may be due to an increased awareness and increased upper gastrointestinal endoscopy rate rather than an increase in real incidence. Criteria for prediction of malignant progression are not available. Multiple gastric carcinoids associated with hypergastrinemia predominantly display nonaggressive behavior. Conservative gastric surgery may be appropriate therapy for such patients.

(Arch Surg. 1995;130:250-256)

Author Affiliations
From the Gastrointestinal Surgical Pathobiology Research Group, Department of Surgery, Yale University School of Medicine and the West Haven Veterans Affairs Medical Center (Drs Modlin, Lawton, Tang, and Darr and Mr Gilligan) and the Department of Pathology, Yale University School of Medicine (Dr West), West Haven, Conn.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Long-acting somatostatin analogues are an effective treatment for type 1 gastric carcinoid tumours
Grozinsky-Glasberg et al.
Eur J Endocrinol 2008;159:475-482.
ABSTRACT | FULL TEXT  

Treatment of Gastric Neuroendocrine Tumors: The Necessity of a Type-Adapted Treatment
Schindl et al.
Arch Surg 2001;136:49-54.
ABSTRACT | FULL TEXT